In addition to small and medium-sized firms, many large national companies …
Boston Scientific Corp. shares climbed after it won approval for ... Analysts also noted that revenue from spinal products was below expectations. The stock was off marginally in recent action to $58.22.
Shares of Boston Scientific Corp. (NYSE:BSX) traded at unusually high volumes for two straight weeks during the recent roller coast on Wall Street, coming in at more than 120 million trades during the week ending July 29 and topping 140 …
The hedge fund now owns almost $300 million in BSX stock, making the medical technology company its largest holding. According to Marketfolly, Greenlight's six largest disclosed long positions are Arkema, Boston Scientific, CIT Group, …
The company has submitted an application for listing on the New York Stock Exchange, filing a registration statement ... and Staples of Framingham, and …
Boston Scientific Corp. (BSX), Monday said it stopped shipment of its top selling implantable cardioverter defibrillators, as it found some of the manufacturing process changes made were not submitted for approval with the US Food and Drug …
Boston Scientific Had a Worthy 4Q15, But Worth Writing Home About? (Continued from Prior Part) Share price movement On February 04, 2016, Boston Scientific Corporation (BSX) released its 4Q15 earnings. The company beat the earnings …
J.’s injury,” he wrote. Johnson & Johnson has moved on from the deal. It received a $705 million breakup fee from Boston Scientific. Since 2004, Johnson & Johnson’s stock has soared 83 percent, and the company is now worth $288 billion. …
As of the latest 13F filings, BSX stock has been purchased in size by: David Einhorn (Greenlight Capital) - he's made BSX a 10.5% position in the fund. John Paulson (Paulson & Co) - 5th largest stock holding, 4.5% of holdings (over 99 million …